Phaseline

Targets › INSR

INSR (Insulin receptor): drug programs, companies and trials

11 programs from 10 companies in 24 trials: 11 Phase 2, 6 Phase 4, 4 Phase 1, 3 Phase 3; Metabolic and endocrine, Ophthalmology, Oncology; next expected readout Dec 2026.

Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. (UniProt, P06213)

Open in Phaseline: the race on INSR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Novo NordiskInsulin icodec
Insulin receptor agonist
INSRPhase 4Diabetes Mellitus, Type 2; Diabetes Mellitus, Type 1Jan 2027
SanofiInsulin Glargine
Insulin receptor agonist
INSRPhase 4Type 2 Diabetes (T2D); Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Type 2 Diabetes …–
Sling Therapeuticslinsitinib
Insulin-like growth factor I receptor inhibitor; Insulin receptor inhibitor
IGF1R, INSRPhase 3Thyroid Eye Disease, TED; Thyroid Eye DiseaseJun 2028
University of Alabama at BirminghamInsulin Aspart
Insulin receptor agonist
INSRPhase 2Diabetes Mellitus, Type 2Dec 2026
MannkindInsulin Human
Insulin receptor agonist
INSRPhase 2Type 1 Diabetes Mellitus; Alzheimer Disease; Type 2 Diabetes; Spinal Cord Injury …Mar 2027
Gilead SciencesBIC/LEN FDC
Combination of integrase strand transfer inhibitor and capsid inhibitor
INSR, POLLENPhase 2HIV-1-infectionDec 2029
Fudan UniversityInsulin (Novolin 30R)
Insulin replacement therapy for glycemic control
INSRPhase 2Pancretic Cancer–
University of California, Los AngelesInsulin Detemir
Insulin receptor agonist
INSRPhase 2Gestational Diabetes–
University of California, Los AngelesInsulin Human, Isophane
Insulin receptor agonist
INSRPhase 2Gestational Diabetes–
DexComInsulin Glargine
Insulin receptor agonist
INSRPhase 1Type 2 DiabetesJan 2027
Gan & Lee Pharmaceuticals.Insulin Degludec
Insulin receptor agonist
INSRPhase 1Type 2 Diabetes–

Conditions

Diabetes Mellitus, Type 2 (5) Type 2 Diabetes (4) Gestational Diabetes (2) Thyroid Eye Disease, TED (1) Thyroid Eye Disease (1) Diabetes Mellitus, Type 1 (1) Pancretic Cancer (1) Type 2 Diabetes (T2D) (1) Metabolic Dysfunction-Associated Steatotic Liver Disease (1) Pregestational Diabetes (1) Diabetes Mellitus in Pregnancy (1) Type 1 Diabetes Mellitus (1)

Modalities

protein or peptide (8), small molecule (3)

Companies

University of California, Los Angeles (2) Sling Therapeutics (1) Novo Nordisk (1) Fudan University (1) Gan & Lee Pharmaceuticals. (1) Sanofi (1) DexCom (1) Mannkind (1) University of Alabama at Birmingham (1) Gilead Sciences (1)

Related targets

IGF1R (1) POLLEN (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.